TCGA-21-1078-01A-01R-0692-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 77
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303735 | — | — | 0.928 |
| 2 | TCGA-95-7948-01A-11R-2187-07 | — | cohortA1 | 0.872 |
| 3 | SRR8943016 | — | — | 0.871 |
| 4 | DRR168565 | — | — | 0.869 |
| 5 | TCGA-A8-A08C-01A-11R-A00Z-07 | — | B | 0.863 |
| 6 | TCGA-DK-A6B0-01A-11R-A31N-07 | — | — | 0.851 |
| 7 | AUR-AFKB-TTM1-A-1-1-R-A742-41 | — | C | 0.847 |
| 8 | MDT-AP-0395 | Med | Medulloblastoma | 0.846 |
| 9 | R90 | — | — | 0.844 |
| 10 | TCGA-S3-AA11-01A-31R-A41B-07 | — | B | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.110 | Remibrutinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |